<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017444</url>
  </required_header>
  <id_info>
    <org_study_id>RG_13-022</org_study_id>
    <secondary_id>2013-003643-31</secondary_id>
    <secondary_id>MR/K015184/1</secondary_id>
    <nct_id>NCT02017444</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.</brief_title>
  <acronym>IIH:DT</acronym>
  <official_title>Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the safety and effectiveness of a 11-βhydroxysteroid dehydrogenase type 1 inhibitor&#xD;
      (AZD4017), in a placebo controlled trial, in acute idiopathic intracranial hypertension (IIH)&#xD;
      IIH is a condition of young, overweight women with characteristic raised intracranial&#xD;
      pressure (pressure around the brain) leading to papilloedema (swelling of the nerve supplying&#xD;
      the eye), visual loss and headaches. Medical literature (Cochrane review) demonstrates there&#xD;
      is little evidence for the treatments used for IIH. Weight control appears the most effective&#xD;
      method of improving symptoms but weight loss is difficult to maintain. 11β-hydroxysteroid&#xD;
      dehydrogenase type 1 (11β-HSD1) is an enzyme which regulates local steroid levels and our&#xD;
      previous research suggests it may influence the production of brain fluid(cerebrospinal fluid&#xD;
      or CSF). 11β-HSD1 levels fall with weight loss and this is associated with with decreased&#xD;
      intracranial pressure.&#xD;
&#xD;
      Our primary outcome is to determine whether AZD4017, an inhibitor of 11β-HSD1, will reduce&#xD;
      the pressure in the brain and as a consequence improve IIH. Patients are eligible to enter&#xD;
      the study if they are between 18-55 years old with acute (&lt;6 months) IIH, signs of active&#xD;
      disease (papilloedema and raised CSF pressure (&gt;25 cmH20)), no other major illnesses and have&#xD;
      no plans for pregnancy during the study period.&#xD;
&#xD;
      This is an MRC funded single centre, phase II, double-blinded, randomised control drug trial.&#xD;
      It will be conducted at the University Hospital Birmingham and the University of Birmingham&#xD;
      will act as Sponsor. Eligible participants will be randomly assigned to AZD4017 or a placebo&#xD;
      ('dummy' with no active drug) for 3 months with a follow up a month later. Investigations&#xD;
      during the study will include bloods, urine samples, pregnancy tests, lumbar punctures, DXA&#xD;
      scans and small fat/skin biopsies. Participants will benefit from increased monitoring and a&#xD;
      potential improvement in their condition.&#xD;
&#xD;
      We hypothesise that specific inhibition of 11β-HSD1 will decrease intracranial pressure and&#xD;
      consequently treat patients with IIH, thus opening a new and entirely novel therapeutic&#xD;
      avenue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2014</start_date>
  <completion_date type="Actual">December 19, 2016</completion_date>
  <primary_completion_date type="Actual">December 19, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tinnitus</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurements (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diplopia</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Obscuration</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Papilloedema</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.&#xD;
The modified Frisén scale for grading papilledema using fundus photography is as follows:&#xD;
Grade 1 - C-Shaped halo with a temporal gap&#xD;
Grade 2 - The halo becomes circumferential&#xD;
Grade 3 - Loss of major vessels as they leave the disc&#xD;
Grade 4 - Loss of major vessels on the disc&#xD;
Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc&#xD;
For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache-associated Disability</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>16 weeks</time_frame>
    <description>The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>16 weeks</time_frame>
    <description>The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT Total Average Retinal Nerve Fibre Layer Thickness (μm)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field Mean Deviation</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log Contrast Sensitivity</measure>
    <time_frame>12 weeks</time_frame>
    <description>The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Idiopathic Intracranial Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo tablet B.D for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD4017 (11b-HSD1 inhibitor)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD4017 400mg tablet B.D. for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4017</intervention_name>
    <arm_group_label>AZD4017 (11b-HSD1 inhibitor)</arm_group_label>
    <other_name>11b-Hydroxysteroid dehydrogenase type 1 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo (matched to AZD4017 arm)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures.&#xD;
&#xD;
          -  Female patients between 18 and 55 years&#xD;
&#xD;
          -  Diagnosis of IIH by the Modified Dandy criteria1 with:&#xD;
&#xD;
               1. acute (&lt;6 months),&#xD;
&#xD;
               2. active disease (papilloedema (Frisen grade greater than or equal to 1),&#xD;
&#xD;
               3. significantly raised ICP &gt; 25cmH2O)&#xD;
&#xD;
               4. normal brain imaging during previous routine diagnostic work up (evaluated by&#xD;
                  either magnetic resonance venography or computerised tomography with venography).&#xD;
&#xD;
          -  Patients must be willing to use one form of highly effective non-hormonal&#xD;
             contraception. This would include:&#xD;
&#xD;
               1. a vasectomised partner (sole partner) or tubal occlusion or&#xD;
&#xD;
               2. copper containing IUD - all of which should be used in addition to a diaphragm or&#xD;
                  cervical/vault caps with barrier contraceptive (condom or spermicidal&#xD;
                  foam/gel/film/suppository)&#xD;
&#xD;
               3. true abstinence (when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Women should have been stable on their chosen method of birth&#xD;
                  control for a minimum of 2 months before entering the trial. Patients must agree&#xD;
                  to undergo a β-hCG pregnancy test and urine dipstick test at screening and urine&#xD;
                  dipstick testing at all trial visits (including the final follow up visit 4 weeks&#xD;
                  after discontinuation of study treatment). Note: the use of contraception and&#xD;
                  pregnancy testing would not be required if the screening LH/FSH levels&#xD;
                  demonstrate the patient is post-menopausal.&#xD;
&#xD;
          -  Participants are able to continue other medications to treat their IIH e.g.&#xD;
             acetazolamide, diuretics but this dose must remain fixed throughout the study.&#xD;
&#xD;
          -  Patients who take aspirin therapy will be asked to discontinue aspirin 3 days prior to&#xD;
             fat and skin biopsy if clinically safe to do so.&#xD;
&#xD;
          -  Placebo treatment for the duration of the study must not be considered detrimental to&#xD;
             the patient.&#xD;
&#xD;
          -  Must be able to understand the consent form and comply with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Optic nerve sheath fenestration.&#xD;
&#xD;
          -  Patients who undergo CSF shunt insertion (which is not elective or pre- planned)&#xD;
             during the study, as a result of deterioration will be withdrawn from the study.&#xD;
&#xD;
          -  Abnormal neurological examination (aside from papilloedema and consequent visual loss&#xD;
             or VI nerve palsy).&#xD;
&#xD;
          -  Subjects with a secondary cause of raised intracranial pressure will be excluded&#xD;
             (venous thrombosis, anaemia, drug causes (lithium, vitamin A, tetracycline or others&#xD;
             deems responsible for the condition).&#xD;
&#xD;
          -  Abnormal CSF contents (except for that compatible with a traumatic LP).&#xD;
&#xD;
          -  Unable to perform a visual field reliably.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Positive hCG or urine dipstick pregnancy test or planning to conceive in the 4 study&#xD;
             months.&#xD;
&#xD;
          -  Have eGFR calculated by MDRD equation of &lt;60ml/min/1.73m2.&#xD;
&#xD;
          -  Have any endocrine disorder, e.g. thyroid dysfunction. This excludes PCOS where there&#xD;
             is a known association to IIH.&#xD;
&#xD;
          -  Suspicion of or known Gilbert's disease.&#xD;
&#xD;
          -  CK &gt;2 x ULN on 2 consecutive measurements.&#xD;
&#xD;
          -  ALT and/or AST &gt;2 x ULN.&#xD;
&#xD;
          -  ALP &gt; ULN.&#xD;
&#xD;
          -  Bilirubin (total) &gt; 2 x ULN.&#xD;
&#xD;
          -  Must not have donated blood within 2 months of screening and avoid further donations&#xD;
             for 4 months following the study.&#xD;
&#xD;
          -  Patient is, at the time of signing the informed consent, a user of recreational or&#xD;
             illicit drugs (including marijuana) or has had a recent history (within the last year)&#xD;
             of drug or alcohol abuse or dependence.&#xD;
&#xD;
          -  Pregnant or breastfeeding mothers, unless willing to discontinue breastfeeding by the&#xD;
             baseline visit.&#xD;
&#xD;
          -  Have uncontrolled systemic hypertension (BP &gt;160/90), on 3 successive measurements on&#xD;
             the morning of the screening visit.&#xD;
&#xD;
          -  Are receiving systemic (including vaginal/rectal) glucocorticoid treatment at the time&#xD;
             of the screening visit. Note: Topical and inhaled are acceptable&#xD;
&#xD;
          -  Are taking any hormone-based medication, including hormone contraceptives, at the time&#xD;
             of screening.&#xD;
&#xD;
          -  Are taking probenecid at the time of the screening visit.&#xD;
&#xD;
          -  Have any screening laboratory abnormality that, in the investigator's judgement, is&#xD;
             considered to be clinically significant or any screening laboratory value which is&#xD;
             outside the Sponsor specified ranges at screening; testing may be repeated but must be&#xD;
             resolved prior to the baseline visit.&#xD;
&#xD;
          -  History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             investigator, may either put the subject at risk because of participation or will&#xD;
             influence the results .&#xD;
&#xD;
          -  History or presence of significant gastrointestinal, hepatic , or renal disease or any&#xD;
             other condition known to interfere with absorption, distribution, metabolism, or&#xD;
             excretion of drugs.&#xD;
&#xD;
          -  Any clinically significant illness, medical/surgical procedure or trauma within 4&#xD;
             weeks of the first administration of IP as judged by the investigator.&#xD;
&#xD;
          -  Have been involved in the planning and/or conduct of the study (applies to both&#xD;
             AstraZeneca staff and/or staff at the study site).&#xD;
&#xD;
          -  Have participated in any other interventional study within 1 month prior to the&#xD;
             screening visit. Participation in the IIH National database or other observational&#xD;
             studies will not prevent enrolment to this study.&#xD;
&#xD;
          -  Previous randomisation for treatment in the present study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Sinclair, MbChb PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Birmingham (Queen Elizabeth Hospital)</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <results_first_submitted>April 1, 2021</results_first_submitted>
  <results_first_submitted_qc>September 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2021</results_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Birmingham</investigator_affiliation>
    <investigator_full_name>Dr Alexandra Sinclair</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>Pseudotumor Cerebri</keyword>
  <keyword>Benign Intracranial Hypertension</keyword>
  <keyword>Headaches</keyword>
  <keyword>Tinnitus</keyword>
  <keyword>Papilledema</keyword>
  <keyword>Blindness</keyword>
  <keyword>Optic Disk</keyword>
  <keyword>Intracranial Hypertension</keyword>
  <keyword>Clinical Trial, Phase 2</keyword>
  <keyword>11beta-Hydroxysteroid Dehydrogenase Type 1</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypertension</mesh_term>
    <mesh_term>Pseudotumor Cerebri</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
        </group>
        <group group_id="P2">
          <title>AZD4017 (11b-HSD1 Inhibitor)</title>
          <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17">NB: One participant did not complete primary outcome.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrawn day after randomisation as found to be ineligible. Did not return for follow up.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
        </group>
        <group group_id="B2">
          <title>AZD4017 (11b-HSD1 Inhibitor)</title>
          <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="8"/>
                    <measurement group_id="B2" value="30.1" spread="5.9"/>
                    <measurement group_id="B3" value="31.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White British</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Asian British - Pakistani</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Asian British - Other Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking acetazolamide (yes/no)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Opening LP pressure (cmCSF)</title>
          <units>cmCSF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="4.8"/>
                    <measurement group_id="B2" value="33.7" spread="6.3"/>
                    <measurement group_id="B3" value="33.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108" spread="42.3"/>
                    <measurement group_id="B2" value="97.9" spread="21.3"/>
                    <measurement group_id="B3" value="102.6" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="16.6"/>
                    <measurement group_id="B2" value="37.3" spread="7.2"/>
                    <measurement group_id="B3" value="39.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache Impact Test 6 (HIT-6) Score</title>
          <units>HIT-6 score (higher is worse)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="8.1"/>
                    <measurement group_id="B2" value="63.8" spread="8.2"/>
                    <measurement group_id="B3" value="63.6" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Frisen grading (Worst eye)</title>
          <description>Papilloedema were evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification. There are 6 grades, 0-5, 5 being the worst.&#xD;
The modified Frisén scale for grading papilledema is as follows:&#xD;
Grade 1 - C-Shaped halo with a temporal gap&#xD;
Grade 2 - The halo becomes circumferential&#xD;
Grade 3 - Loss of major vessels as they leave the disc&#xD;
Grade 4 - Loss of major vessels on the disc&#xD;
Grade 5 - Grade IV + partial or total obscuration of all vessels on the disc</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of Pulsatile Tinnitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of visual loss</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of diplopia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of Visual obscuration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of headache</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intracranial Pressure</title>
        <description>ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Intracranial Pressure</title>
          <description>ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12</description>
          <units>cmCSF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="5.9"/>
                    <measurement group_id="O2" value="-4.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tinnitus</title>
        <description>The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Tinnitus</title>
          <description>The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anthropometric Measurements (BMI)</title>
        <description>The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Anthropometric Measurements (BMI)</title>
          <description>The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="8.4"/>
                    <measurement group_id="O2" value="37.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Loss</title>
        <description>The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Loss</title>
          <description>The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diplopia</title>
        <description>The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Diplopia</title>
          <description>The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Obscuration</title>
        <description>The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Obscuration</title>
          <description>The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache</title>
        <description>The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Headache</title>
          <description>The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12</description>
          <units>LogMAR (log of the minimum angle of reso</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LVA worst eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.22"/>
                    <measurement group_id="O2" value="0.08" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 LVA worst eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.18"/>
                    <measurement group_id="O2" value="0.06" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Papilloedema</title>
        <description>The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.&#xD;
The modified Frisén scale for grading papilledema using fundus photography is as follows:&#xD;
Grade 1 - C-Shaped halo with a temporal gap&#xD;
Grade 2 - The halo becomes circumferential&#xD;
Grade 3 - Loss of major vessels as they leave the disc&#xD;
Grade 4 - Loss of major vessels on the disc&#xD;
Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc&#xD;
For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711.</description>
        <time_frame>12 weeks</time_frame>
        <population>NB: assessment missed for one participant at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Papilloedema</title>
          <description>The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.&#xD;
The modified Frisén scale for grading papilledema using fundus photography is as follows:&#xD;
Grade 1 - C-Shaped halo with a temporal gap&#xD;
Grade 2 - The halo becomes circumferential&#xD;
Grade 3 - Loss of major vessels as they leave the disc&#xD;
Grade 4 - Loss of major vessels on the disc&#xD;
Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc&#xD;
For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711.</description>
          <population>NB: assessment missed for one participant at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frisen grade 0 baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 0 week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 1 baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 1 week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 2 baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 2 week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 3 baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 3 week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 4 baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 4 week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 5 baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frisen grade 5 week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache-associated Disability</title>
        <description>The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Headache-associated Disability</title>
          <description>The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache.</description>
          <units>Score on HIT-6 scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="7.9"/>
                    <measurement group_id="O2" value="60.1" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.</description>
          <units>AEs related to intervention</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.</description>
          <units>Serious adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OCT Total Average Retinal Nerve Fibre Layer Thickness (μm)</title>
        <description>The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>NB: assessment missed in participants of both arms due to centre capacity.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>OCT Total Average Retinal Nerve Fibre Layer Thickness (μm)</title>
          <description>The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12</description>
          <population>NB: assessment missed in participants of both arms due to centre capacity.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total average retinal nerve fibre layer baseline worst ete</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.4" spread="83"/>
                    <measurement group_id="O2" value="152" spread="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total average retinal nerve fibre layer week 12 worst eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.2" spread="78.7"/>
                    <measurement group_id="O2" value="139.7" spread="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Field Mean Deviation</title>
        <description>The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>NB: assessment at 12 weeks not completed for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Field Mean Deviation</title>
          <description>The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12</description>
          <population>NB: assessment at 12 weeks not completed for 2 participants.</population>
          <units>Visual field mean deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MD worst eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="6.8"/>
                    <measurement group_id="O2" value="-6.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 MD worst eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="3.1"/>
                    <measurement group_id="O2" value="-3.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log Contrast Sensitivity</title>
        <description>The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>NB: assessment at 12 weeks not completed for 2 participants (placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
          </group>
          <group group_id="O2">
            <title>AZD4017 (11b-HSD1 Inhibitor)</title>
            <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
          </group>
        </group_list>
        <measure>
          <title>Log Contrast Sensitivity</title>
          <description>The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12</description>
          <population>NB: assessment at 12 weeks not completed for 2 participants (placebo).</population>
          <units>Log contrast senstivity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LCS worst eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.16"/>
                    <measurement group_id="O2" value="1.63" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 LCS worst eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.12"/>
                    <measurement group_id="O2" value="1.65" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matched placebo tablet B.D for 12 weeks&#xD;
Placebo: Matched placebo (matched to AZD4017 arm)</description>
        </group>
        <group group_id="E2">
          <title>AZD4017 (11b-HSD1 Inhibitor)</title>
          <description>AZD4017 400mg tablet B.D. for 12 weeks&#xD;
AZD4017</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>IIH exacerbation</sub_title>
                <description>IIH exacerbation requiring acute intervention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eyes, ear, nose, throat</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-intestinal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Genito-urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>tiredness; hot sweats; flu like symptoms; disrupted sleep; toothache/infection; breast pain; menstrual problems for more than 3 weeks; mouth ulcers; a cold; transient nausea and height headaches</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A duration of 12 weeks was chosen for the evaluation of safety and tolerability, being the longest duration of dosing to date with AZD4017. This may not have been enough for meaningful evaluation of clinical outcomes.&#xD;
The sample size is small, which may have reduced power and limited meaningful evaluation of clinical measures: the trial was not designed to establish significant changes in the secondary clinical outcome measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Alex Sinclair</name_or_title>
      <organization>University of Birmingham</organization>
      <phone>+44 121 415 9125</phone>
      <email>a.b.sinclair@bham.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

